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Abstract
Background: Na
+/I
- symporter (NIS)-mediated iodide uptake allows radioiodine therapy for thyroid cancer. NIS is
also expressed in breast tumors, raising potential for radionuclide therapy of breast cancer. However, NIS
expression in most breast cancers is low and may not be sufficient for radionuclide therapy. We aimed to identify
biomarkers associated with NIS expression such that mechanisms underlying NIS modulation in human breast
tumors may be elucidated.
Methods: Published oligonucleotide microarray data within the National Center for Biotechnology Information
Gene Expression Omnibus database were analyzed to identify gene expression tightly correlated with NIS mRNA
level among human breast tumors. NIS immunostaining was performed in a tissue microarray composed of 28
human breast tumors which had corresponding oligonucleotide microarray data available for each tumor such that
gene expression associated with cell surface NIS protein level could be identified.
Results and Discussion: NIS mRNA levels do not vary among breast tumors or when compared to normal breast
tissues when detected by Affymetrix oligonucleotide microarray platforms. Cell surface NIS protein levels are much
more variable than their corresponding NIS mRNA levels. Despite a limited number of breast tumors examined, our
analysis identified cysteinyl-tRNA synthetase as a biomarker that is highly associated with cell surface NIS protein
levels in the ER-positive breast cancer subtype.
Conclusions: Further investigation on genes associated with cell surface NIS protein levels within each breast
cancer molecular subtype may lead to novel targets for selectively increasing NIS expression/function in a subset of
breast cancers patients.
Background
The Na
+/I
- symporter (NIS) (also known as SLC5A5,
solute carrier family 5 member 5) is a transmembrane
glycoprotein that uptakes iodide into the thyroid follicu-
lar cells for the biosynthesis of thyroid hormones.
Accordingly, radioiodine has been used to ablate thyroid
tumors and metastases. NIS is induced in the breast
during lactation to accumulate iodide for the nursing
infant to synthesize its own thyroid hormones [1,2]. NIS
has also been detected in the majority of breast tumors,
raising promise for radionuclide therapy of breast cancer
[3-6]. However, only a minority of NIS-positive breast
tumors had detectable radionuclide accumulation [4-6],
indicating that strategies for selectively increasing cell
surface NIS expression are critical for realizing radionu-
clide therapy of breast cancer patients.
Mechanisms underlying NIS modulation in human
breast cancer are poorly understood. NIS expression is
increased in breast tumors [3], suggesting that NIS
expression is correlated with malignant transformation.
However no biomarkers of breast cancer progression
such as breast tumor subtype, hormone receptor status,
or tumor grade [3,7-9] have been reported to correlate
with NIS protein levels among tumors. The MCF-7 cell
line is the only human breast cancer cell line with indu-
cible endogenous NIS expression. Kogai et al. [10] first
reported that trans-retinoic acid (tRA) induces NIS
mRNA in MCF-7 cells at the transcriptional level.
Moreover, a combination of tRA and hydrocortisone
(tRA/H), further increases tRA-induced NIS expression/
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any medium, provided the original work is properly cited.function in MCF-7 cells [11-15], most likely by increas-
ing NIS mRNA stability [11]. While NIS induction by
tRA has been observed in MCF-7 cell xenografts in vivo
[12], normal mammary glands of mice [13], and the
PyVT transgenic mouse model [12], Kogai et al. [11,12]
stated that the dose of tRA required for maximum NIS
induction in MCF-7 cell xenografts in vivo was ten-fold
greater than the maximum tolerable tRA dose in
humans. In this study, we aimed to identify biomarkers
that correlate with NIS expression in order to elucidate
mechanisms of NIS regulation in human breast tumors
such that novel strategies for selectively increasing NIS
expression/function in breast cancers patients can be
developed.
Methods
Publicly Available Oligonucleotide Microarray Datasets
Published microarray datasets from NCBI GEO database
[16] (http://www.ncbi.nlm.nih.gov/geo/) that detected
genome wide expression in breast tumors were exam-
ined in our analysis: GSE3744 [17] (Affymetrix HG
U133 Plus 2.0 Array); GSE10797 (unpublished, HG
U133 Plus 2.0); GSE1561 [18] (Affymetrix HG U133A
Array); GSE6367 [19] (Affymetrix HG U95Av.2);
GSE6434 (unpublished data, Affymetrix HG U95A);
GSE3155 [20] (Agilent-012391 Whole Human Genome
Oligo Microarray and Applied Biosystems Human Gen-
ome Survey Microarray Version 1); GSE6861 [21] (Affy-
metrix Human X3P Array); GSE14548 [22](Affymetrix
Human X3P Array).
Cell Culture and RNA Extraction
MCF-7 human breast cancer cells were maintained in a
1:1 ratio of DMEM and Ham’s F-12 media (Gibco), 10%
FBS (Invitrogen) and 1% penicillin/streptomycin. MCF-7
cells were treated with DMSO vehicle, tRA, or tRA/H
for 12 hours, and total RNA was extracted with Trizol
reagent (Invitrogen) and chloroform (Sigma).
Generation of microarray data and real-time qRT-PCR
RNA integrity and quantity were determined by the
Agilent Bioanalyzer 2100 by the MicroArray Shared
Resource (MASR) for the OSU Comprehensive Cancer
Center (OSUCCC). The MASR performed sample pre-
paration and labeling, chip hybridization and staining,
chip scanning and initial image analysis according to
Affymetrix instructions. Briefly, cRNA was generated
using GeneChip T7-Oligo(dT) Promoter Primers kit
and the raw data was generated with Affymetrix Gene-
Chip Operating Software on a Human Genome U133
plus 2.0 Affymetrix platform. Raw microarray data
from MCF-7 breast cancer cells treated with DMSO,
tRA and tRA/H are included on the GEO database
(GSE32161).
Quantitative RT-PCR was performed using Power
SYBR Green PCR Master Mix (Applied Biosystems).
NIS was amplified with primers: 5’-CCGGATCAACCT-
CATGGACT-3’ and 5’-CTGAGGGTGCCACTGTAAG-
3’. Human GAPDH was amplified with primers: 5’-
CATCATCTCTGCCCCCTCTGCTG-3’ and 5’-GCAAT
GCCAGCCCCAGCGTCAAAGG-3’. PCR using the ABI
7900HT instrument (Applied Biosystems) was per-
formed by OSUCCC Nucleic Acids Shared Resource.
Breast tumor tissue microarray with corresponding, pre-
existing microarray data
A breast tumor tissue microarray composed of 28
tumors of various histological and molecular subtypes
was previously described by Lu et al. [23] (GEO data-
base, GSE5460). Briefly, all samples were cases of pri-
mary tumors from untreated breast cancers with known
axillary lymph node status. Information on invasive
tumor subtype, molecular subtype, estrogen receptor
(ER) status, progesterone receptor (PR) status, Her-2/
neu status, p53 status, Bloom-Richardson grade and the
presence of lymph node metastases were also obtained
for each tumor, as described by Lu et al. [23]. Each
tumor had available corresponding gene expression data
from the HG-U133 Plus 2.0 microarray platform.
Immunohistochemistry
Immunohistochemistry was performed as described by
our previous study [24]. Tissues were incubated with
either p442 anti-hNIS (1:25) or anti-CARS (Sigma,
1:500) primary antibodies for one hour. The level of cell
surface NIS protein in each case was scored on a scale
of 0, 1+, 2+ and 3+, using criteria analogous to the eva-
luation of Her-2/neu staining. For CARS protein,
tumors scored as 0 or 1+ were considered negative and
tumors scored as 2 or 3+ were considered positive.
Statistical Analyses
Oligonucleotide microarray analysis For all the micro-
array studies, background correction and normalization
was performed and gene expression level was summar-
ized over probes using the RMA method [25]. Normal-
ized data sets are included on the GEO database
(GSE32161). A filtering method based on the percentage
of samples with expression values above noise level was
applied to filter out probe-sets with little or no expres-
sion. Generalized linear models based on Limma [26]
were used to detect differentially expressed genes
between NIS “0” and NIS “2+ and 3+” breast tumor
groups, as well as between DMSO-, tRA- or tRA/H-trea-
ted MCF-7 cells. In order to improve the estimates of
variability and statistical tests for differential expression,
a variance shrinkage method was employed [27]. The
differentially expressed genes were claimed based on the
p-values by controlling the average number of false
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Page 2 of 14positives at 1 [28] over all the tested probe sets. Fold
changes of at least 1.5 were used to further reduce the
list of significant probe sets after controlling the number
of false positives. In order to detect NIS-associated
genes, Spearman rank correlation and/or Pearson corre-
lation method was applied using the normalized and fil-
tered microarray data. Genes with absolute correlation
coefficients greater than 0.6 and p-values above the sig-
nificance level (controlling 1 false positive over all the
tested probe-sets) were selected. Differentially expressed
genes or NIS correlated genes were subjected to hier-
archical clustering using Euclidean distance based on
their relative expressions and average linkage clustering
method using software MEV [29].
Bioinformatics Tools After NIS-associated genes were
identified by Linear Models, Pearson correlation and
Spearman correlation analyses, bioinformatics tools were
used for data analysis. Ingenuity Pathway Analysis (Inge-
nuity Systems) allowed us to identify cell signaling path-
ways or functional categories that were over-represented
among the NIS-associated genes. Ingenuity Pathway
Analysis also compared and contrasted gene lists identi-
fied by each statistical method, as indicated by Venn
diagrams. ToppFun was also used to determine whether
the identified NIS-associated genes were regulated by a
common transcription factor [30].
Correlation studies Fisher’s exact test was used to test
the association between cell surface NIS protein levels
and HER-2 status, tumor type, ER status, PR status, p53
mutation status, and CARS protein.
Results
NIS mRNA levels detected by HG U133A oligonucleotide
microarray (NIS probe set ID 211123_at) do not vary
among breast tumors or when compared to normal
breast tissue
NIS expression among breast tumors within the
GSE3744 dataset [17] was detected by the 211123_at
NIS probe set on the Affymetrix HG-U133 Plus 2.0.
However, the 211123_at NIS probe set did not detect
significant differences in NIS mRNA levels despite that
not all breast tumors have been reported to express NIS
mRNA [5,9,31]. As shown in Figure 1A, log2 NIS
mRNA levels detected among normal, non-lactating
breast tissues (mean 5.1 ± 0.42, light gray line)w e r e
comparable to breast tumor NIS mRNA levels (ER+, 5.4
±0 . 3 8 ,dark gray line, and ER-, 5.2 ± 0.51, black line).
NIS mRNA levels detected by the 211123_at NIS probe
set deviated by less than 10% of the mean. In compari-
son, as shown in Figure 1B, log2 ERa mRNA levels were
greater in ERa-positive tissues compared to ERa-nega-
tive tumors. Overall, ER mRNA level deviated by up to
38% of the mean. Taken together, the NIS probe set
may not have sufficient sensitivity to detect NIS
variability among tumors and/or NIS protein levels may
be primarily regulated at the post-mRNA level.
Only modest increases in NIS mRNA expression were
detected in tRA- and tRA/H-treated MCF-7 breast cancer
cells by the 211123_at NIS probe set
In agreement with previous reports [10,11], qRT-PCR
detected 7-fold and 12.6-fold increases in NIS mRNA
levels with tRA and tRA/H treatment of MCF-7 cells,
respectively. Oligonucleotide microarray technology only
detected 2.1- and 2.4-fold increases in tRA- and tRA/H-
induced NIS mRNA levels, respectively (Figure 2A).
Gene expression profiles of tRA-treated MCF-7 cells
were compared to DMSO vehicle-treated MCF-7 cells
(Additional File 1) with the objective of identifying
genes contributing to tRA-induced NIS expression.
However, NIS was not among the differentially
expressed genes. It is important to note that many
genes previously reported to be up-regulated by tRA
treatment were identified, including cytochrome P450,
G-protein coupled receptor, S100 calcium binding pro-
tein, LY6/PLAUR domain containing protein, lamins A
and C, ceruloplasmin and transforming growth factor b
[reviewed in [32]], thus validating our method of analy-
sis. These results further indicate that the 211123_at
NIS probe set is not sufficient to detect increased NIS
mRNA level in tRA/H treated MCF-7 cells.
Since the 211123_at NIS probe set is composed of 11
perfect match probes, we next examined the extent of
tRA- and tRA/H-induced NIS mRNA levels detected by
each individual probe to determine whether this may
contribute to the low sensitivity of the NIS probe set.
The extent of change in signal was highly variable
among the 11 probes. While most probes indicated
minimal increases in signal with tRA and tRA/H treat-
ment, one probe showed no increase in signal intensity
with tRA- or tRA/H treatment (Figure 2B, probe 2)a n d
another decreased in intensity (Figure 2B, probe 7).
Selecting for individual probes that most accurately
reflect variability in NIS mRNA expression may improve
the detection of NIS mRNA by the 211123_at NIS
probe set.
Variability in NIS mRNA expression among breast tumors
could not be detected by additional oligonucleotide
microarray platforms
A ss h o w ni nT a b l e1 ,N I Sm R N Ae x p r e s s i o na m o n g
breast tumors deviated from the mean by less than 12%
in two additional datasets utilizing the HG U133 Plus
2.0 platform, confirming that the sensitivity of the
211123_at probe set was too low to detect variability in
NIS mRNA levels among breast cancers. We analyzed
four additional microarray platforms that detected gen-
ome-wide expression among breast tumors on the GEO
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Page 3 of 14Figure 1 NIS mRNA levels detected by HG U133A oligonucleotide microarray (NIS probe set ID 211123_at) do not vary among breast
tumors or normal breast tissue. The Gene Expression Omnibus dataset GSE3744 consists of normalized log2-transformed genome-wide
expression of 7 normal breast tissues, 15 normal ER+ breast tumors and 24 ER- breast tumors. NIS and ER mRNA expression are plotted for each
individual breast tissue sample and horizontal lines represent mean expression values among normal breast tissues (light gray line), ER+ breast
tumors (dark gray line), and ER- breast tumors (black line). Mean ± standard deviation are also indicated. (A) NIS mRNA levels of breast tissues in
the GSE3744 Gene Expression Omnibus dataset did not significantly vary among normal breast tissues (mean 5.1 ± 0.42, range 4.5-5.7), ER+
breast tumors (mean 5.4 ± 0.39, range 4.6-6.0) or ER- breast tumors (mean 5.2 ± 0.51, range 4.4-6.4). (B) In contrast, ER mRNA levels for normal
breast tissues (mean 10.1 ± 1.56, light gray line; range 7.4-11.9) and ER+ breast tumors (mean 10.9 ± 2.29, dark gray line; range 5.5-13.9) were
significantly greater than ER- tumors (mean 4.2 ± 1.6, black line; range 1.9-8.2).
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Page 4 of 14Figure 2 Only modest increases in NIS mRNA expression were detected in tRA- and tRA/H-treated MCF-7 breast cancer cells by the
211123_at NIS probe set. MCF-7 human breast cancer cells were treated with DMSO vehicle, tRA(1 μM) or tRA(1 μM)/H(1 μM) for 12 hours,
total RNA was harvested, and NIS mRNA was detected by parallel qRT-PCR and microarray (HG U133 Plus 2.0) experiments. The quantification of
hNIS by qRT-PCR was normalized according to the level of GAPDH and the data are presented as a fold change in NIS mRNA over GAPDH
control. (A) While qRT-PCR detected 7.0- and 12.6-fold increases in NIS mRNA with tRA and tRA/H treatments, respectively, only 2.1- and 2.4-fold
increases were detected by microarray. The mean ± standard deviations of two independent trials are plotted. (B) Signal intensities detected by
the 11 individual perfect match probes within the NIS probe set are depicted for two independent trials of DMSO-, tRA- and tRA/H-treated MCF-
7 cells. The figure depicts variability in the extent of change in NIS mRNA among all 11 probes with tRA and tRA/H treatment. Fold changes in
normalized NIS mRNA levels are also indicated for each individual trial.
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these four additional microarray platforms, as they var-
ied according to probe length, quantity of individual
perfect match probes, and target sequence within the 3’
region of NIS cDNA. NIS mRNA level deviated by less
than 12% of the mean regardless of the NIS probe set/
microarray platform utilized, suggesting that NIS varia-
bility among breast cancers cannot be reliably detected
by several Affymetrix platforms. Moon et al. [5] pre-
viously reported that nearly all breast tumors examined
(N = 24/25) had detectable NIS mRNA by RT-PCR and
the extent of variation in NIS mRNA levels among
tumors was about 10-fold (median 0.6 ± 0.27, range
0.10-1.27 arbitrary units).
Cell surface NIS protein levels are more variable than
corresponding NIS mRNA levels detected by
oligonucleotide microarray
To identify gene expression profiles associated with cell sur-
face NIS protein levels, NIS-immunostaining was per-
formed using a TMA with cDNA microarray data available
for each breast tumor (GEO dataset GSE5460)[23]. Two
cores extracted from different regions of each tumor were
included on the TMA and independently scored by three
individuals, including an experienced breast cancer patholo-
gist (R.J.). Among the tumors on the TMA, 5 (18%) were
scored 0, 6 (21%) were 0/1+, 7 (25%) were 1+, 5 (18%) were
1/2+, 3 (11%) were 2+, and 2 (7%) were assigned a score of
3+. Similar to our previous study [24], only 7% (3+) to 18%
(2-3+) of breast tumors strongly expressed NIS protein and
18% (0+) of breast tumors were considered negative for
NIS protein. Also consistent with previous reports [3,7-9],
there was no correlation between cell surface NIS protein
a n db r e a s tt u m o rs u b t y p e( p=0 . 5 0 ) ,h o r m o n er e c e p t o rs t a -
tus (ER, p = 0.17; PR, p = 0.58; Her-2/neu, p = 0.97), p53
status (p = 0.71), tumor grade (p = 0.57), or the presence of
lymph node metastases (p = 0.59) (Table 2).
As expected, there was no correlation between NIS
mRNA levels detected by the 211123_at NIS probe set
and cell surface NIS protein levels (Figure 3). Indeed,
NIS mRNA levels did not vary between cell surface
NIS-negative tumors (0+) and cell surface NIS-positive
tumors (3+). Thus, identifying gene expression profiles
associated with cell surface NIS protein may be a more
effective approach than identifying gene expression pro-
files associated with NIS mRNA levels.
Linear Models Analysis identified 44 genes to be
significantly up- or down-regulated in cell surface NIS-
positive breast tumors compared to cell surface NIS-
negative breast tumors
Considering the inherent limitations and subjectivity
associated with quantifying cell surface NIS protein
levels by immunohistochemical staining, we initially
identified gene expression profiles associated with NIS
protein by comparing tumors that were strongly positive
for cell surface NIS (2+, n = 3; 3+, n = 2) and negative
for cell surface NIS (0+, n = 4). Forty four genes were
significantly differentially regulated according to cell sur-
face NIS protein level by Linear Models analysis, with 42
up-regulated and 2 down-regulated in NIS-positive
breast tumors compared to NIS-negative breast tumors.
Clustering analysis of the 44 identified genes appears to
group tumors based on their molecular subtypes rather
than distinguishing NIS-positive tumors from NIS-nega-
tive tumors (Additional File 2: Figure A). However, the
distinction in gene expression profiles between NIS-posi-
tive basal tumors and NIS-negative basal tumors was read-
ily apparent by the heat map (breast tumor ID 1, 2 vs. 27,
28). Indeed, scatter plots show that mRNA levels of
IGFBP2 and SPIB, the two most differentially regulated
genes, were significantly different between NIS-negative (0
+) versus NIS-positive (3+) breast tumors (Additional File
2: Figure B). Taken together, while the power of this Lin-
ear Models analysis was limited by the small number of
breast tumors examined, this analysis suggests that bio-
markers associated with cell surface NIS expression may
vary according to breast cancer molecular subtypes.
Pearson and Spearman correlation analyses identified
genes positively- and negatively-correlated with cell
surface NIS protein levels in breast cancer
Pearson correlation analysis identified 63 genes that
exhibited a linear correlation (r ≥ 0.6) with cell surface
Table 1 NIS mRNA levels do not vary among human breast tumors as detected by oligonucleotide microarray
technology
Microarray Platform NIS Probe Set ID Probe Length Target (NIS
Sequence)
Standard Deviation
Affymetrix HG U133 Plus 2.0 211123_at 25-mer (n* = 11) 5’-1521-1991-3’ Avg. 0.23, Range 0.17-0.28 (N
# =2 )
Affymetrix HG U95A 32459_at 25-mer (n* = 16) 5’-1522-1998-3’ Avg. 0.20, Range 0.14-0.26 (N
# =2 )
Affymetrix Human X3P G2887404_3p_at 25-mer (n* = 11) 5’-1693-1992-3’ Avg. 0.18, Range 0.18-0.18 (N
# =2 )
Applied Biosystems Human Survey Microarray V1 193100 60-mer (n* = 1) Proprietary 0.21 (N
# =1 )
Agilent-012391 Human Genome 30047 60-mer (n* = 1) 5’-1707-1767-3’ 0.13 (N
# =1 )
*, Number of perfect match oligonucleotide probes within the NIS probe set.
#, Number of datasets examined that utilized each respective microarray platform.
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cluster analysis did not appear to group breast tumors
according to molecular subtype or cell surface NIS levels
(Additional File 3: Figure A). Since Pearson correlation
is more susceptible to outliers, Spearman rank correla-
tion was also performed to identify gene expression that
was monotonically correlated with cell surface NIS
levels. Spearman rank correlation identified 64 genes,
and the cluster analysis appeared to group tumors
according to cell surface NIS protein level rather than
molecular subtype (Additional File 3: Figure B).
NIS gene was not included among the positively cor-
related genes identified by either analysis, most likely
due to the insensitivity of the 211123_at NIS probe set.
No over-represented cell signaling pathways or func-
tional categories of genes were identified by Ingenuity
Pathway Analysis (Ingenuity Systems) and no transcrip-
tion factors commonly associated with the identified
genes were found by ToppFun (ToppGene Suite)[30].
There were 30 genes in common between Pearson and
Spearman rank correlation analyses, suggesting that at
least 47% of the 64 genes identified by Spearman corre-
lation exhibited linear relationships with cell surface NIS
levels. Scatter plots showed that both QRICH1 and ND6
mRNA levels appeared to have linear relationships with
cell surface NIS protein levels, however, the extent of
variation in QRICH1 mRNA level according to NIS cell
surface levels is limited (Additional File 3: Figure C).
Pearson correlation, Spearman rank correlation, and
Linear Models analyses identified CARS and PYROXD1 to
be highly associated with cell surface NIS protein in
breast cancer
Genes commonly identified by Pearson correlation,
Spearman rank correlation, and Linear Models analyses
were further examined. As shown by the Venn diagram
in Figure 4A, cysteinyl-tRNA synthetase (CARS) and
two different probe sets targeting pyridine nucleotide-
disulphide oxidoreductase domain (PYROXD1) were
identified by each statistical analysis. Scatter plots
Table 2 Summary of cell surface NIS protein levels and characteristics of 28 breast tumors included on the TMA
Tumor
ID
Cell surface NIS
protein
Molecular
Subtype
Invasive
Tumor Type
Bloom-
Richardson Grade
PR
Status
ER
Status
Her-2/neu
Status
P53
Status
Lymph Node
Metastases
1 0 Basal D III - - - - -
2 0 Basal D III - - - - -
3 0 ER+ D II +Low + - + +
4 0 HER2/neu D III - + + - +
5* 0 HER2/neu M II + + + - +
6* 0/1 HER2/neu D III - - + + +
7 0/1 ER+ D III + + + Unknown -
8 0/1 ER+ L I - + - - +
9 0/1 ER+ D III + + - + +
10 0/1 HER2/neu L III + + + Unknown +
11 0/1 ER+ L II + + - - +
12 1+ HER2/neu D III - - + + -
13 1+ Basal D III - - - + +
14 1+ HER2/neu D III - - + + +
15 1+ HER2/neu D III - - + - +
16 1+ ER+ L I + + - Unknown +
17* 1+ ER+ L II +Low + - +Low +
18* 1+ HER2/neu D III +Low + - +Low Unknown
19 1+/2+ HER2/neu D III - - + - -
20 1+/2+ Basal D III - - - + -
21 1+/2+ Basal D III - - - + -
22 1+/2+ Basal M III - - + + +
23 1+/2+ ER+ D III + + - Unknown +
24 2+ ER+ D II - - - - -
25 2+ ER+ D II + + - - +
26 2+ HER/neu L III - - + + +
27 3+ Basal D III - - - + +
28 3+ Basal D III - - - - +
*: Tumors not included in microarray analysis due to microarray data quality; +: Positive; +Low: Positive-Low; -: Negative; D: ductal carcinoma; L: Lobular
carcinoma; M: Mixed ductal and lobular carcinoma; ER: estrogen receptor.
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correlated with cell surface NIS protein level but also
differentially regulated between NIS-positive and NIS-
negative breast tumors (Figure 4B).
CARS protein is associated with cell surface NIS protein
among ER+ breast tumors
Immunostaining was performed on a different TMA
enriched for NIS-positive tumors (42 tumors, including
19 NIS-positive tumors (2+/3+) and 23 NIS-negative
tumors (0+/1+) to confirm the results of our
oligonucleotide microarray analysis. Unfortunately, there
was no antibody available for confirmatory experiments
involving PYROXD1, as this gene codes for the pyridine
nucleotide-disulphide oxidoreductase domain, a domain
found among proteins involved in disulphide bond for-
mation [33]. As shown in Figures 5A and 5B, CARS
showed a pattern of over- or under-expression in NIS-
positive or negative tumor groups, respectively, consis-
tent with our oligonucleotide microarray data. However,
this trend did not reach statistical significance among all
42 breast tumors (p > 0.05). It was not until cell surface
Figure 3 Cell surface NIS protein levels are more variable than corresponding NIS mRNA levels detected by oligonucleotide
microarray. A human breast tumor TMA composed of 28 breast tumors with corresponding cDNA microarray data was immunostained with
the p442 anti-hNIS antibody and each tumor was evaluated according to the level of cell surface NIS protein on a scale of 0, 0/1+, 1+, 1+/2+, 2
+ and 3+. NIS mRNA levels detected by the 211123_at NIS probe set of the HG U133 Plus 2.0 Affymetrix microarray platform were examined
and compared among breast tumors expressing each assigned level of cell surface NIS protein. Maximum, minimum and median NIS mRNA
levels for each level of cell surface NIS are indicated. As shown by the box and whisker plot, there was no correlation between NIS mRNA and
cell surface NIS protein among breast tumors. The length of the box represents the interquartile range (i.e., the middle 50% of the data). The
median (line through the middle of each box), the lower quartile (bottom line of each box), and the upper quartile (top line of each box) are also
specified on the plot for each level of cell surface NIS protein. The sample minimum and maximum values are represented as T-shaped lines
extending from the ends of the box. Maximum outliers (gray squares) and minimum outliers (black diamonds) are also plotted. Representative
images of breast tumors scored as 0 (18%, n = 5), 0/1+ (21%, n = 6), 1+ (25%, n = 7), 1+/2+ (18%, n = 5), 2+ (11%, n = 3) and 3+ (7%, n = 2)
for cell surface NIS protein (denoted by arrows) are also shown (400×).
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Page 8 of 14Figure 4 CARS and PYROXD1 genes were identified by Pearson correlation, Spearman rank correlation, and Linear Models analyses.
(A) Overlapping genes identified by the Spearman rank correlation, Pearson correlation and Linear Models microarray analyses are indicated by
the venn diagram. Two PYROXD1 probesets (denoted as PYROXD1A and PYROXD1B) and CARS (probeset ID 212971_at) were identified by all three
analyses. (B) The box and whisker plot examines and compares normalized mRNA expression of CARS and PYROXD1 among breast tumors
scored as 0, 0/1+, 1+, 1+/2+, 2+ or 3+ for cell surface NIS protein. As shown by the scatter plot, CARS and PYROXD1 mRNA levels correlate with
cell surface NIS protein levels. The length of the box represents the interquartile range (i.e., the middle 50% of the data). The median (line
through the middle of each box), the lower quartile (bottom line of each box), and the upper quartile (top line of each box) are also specified on
the plot for each level of cell surface NIS protein. The sample minimum and maximum values are represented as T-shaped lines extending from
the ends of the box. Maximum outliers (gray squares) and minimum outliers (black diamonds) are also plotted.
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Page 9 of 14Figure 5 CARS protein is associated with cell surface NIS protein among ER+ breast tumors. Cell surface NIS and CARS protein were
probed by immunohistochemistry on another breast tumor TMA composed of 42 tumors of various histological subtypes and tumors were
assigned a score of 0, 1+, 2+ and 3+ for each respective protein. Scores of 0 and 1+ were considered to be negative and scores of 2+ and 3+
were considered positive. (A) Positive and negative NIS and CARS immunostaining from two representative breast tumors are shown. (B) While
there appeared to be a trend of over- or under-expression of CARS in all NIS positive and negative tumors, respectively, the correlation did not
achieve statistical significance by Fisher’s exact test (P > 0.05). (C) Interestingly, CARS protein significantly correlated with breast tumors of ER+
histological subtype but not tumors triple negative for ER, PR and Her-2/neu.
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Page 10 of 14NIS and CARS protein levels were examined in only ER
+ breast tumors (n = 32) that the association between
cell surface NIS and CARS reached statistical signifi-
cance (Figure 5C, p < 0.05). In contrast, triple-negative
breast tumors (ER-, PR-, and Her-2/neu-, n = 8) showed
no relationship between cell surface NIS protein and
CARS protein (Figure 5C, p > 0.05), again indicating
that biomarkers of NIS protein level may vary among
different breast cancer subtypes.
Discussion
NIS variability among breast cancers could not be reli-
ably detected by any one of multiple Affymetrix plat-
forms included in our study. Instead, we identify CARS
as a biomarker that is correlated with cell surface NIS
levels among ER+ breast cancers. Our analysis indicates
that the underlying mechanism of NIS modulation is
most likely to be different among different subtypes of
breast cancer. Gene expression profiling for biomarkers
associated with cell surface NIS protein levels among
breast cancer subtypes with a larger sample number is
warranted. Biomarkers identified will not only help to
recognize subsets of breast cancer patients likely to ben-
efit from NIS-targeted radionuclide therapy, but may
also serve as novel targets for developing strategies to
selectively increase NIS-mediated radionuclide uptake in
corresponding breast cancer subtypes.
Microarray technology is known to underestimate fold
changes in gene expression compared to qRT-PCR. Stu-
dies have reported significantly higher changes in
mRNA levels detected by qRT-PCR compared to micro-
array technology [34], as microarray technology is based
on hybridization rather than gene amplification. In some
cases, saturation of microarray probes has been reported
to contribute to underestimations in gene expression
[35]. Moreover, while individual probes within probe
sets of microarray platforms are designed to improve
signal-to-noise ratio and minimize non-specific hybridi-
zation, the variability in signal intensity detected by
these probes can introduce error [36]. Alternatively, NIS
mRNA levels quantified by an qRT-PCR array may be
better equipped to distinguish between NIS-positive and
NIS-negative breast tumors for gene expression profil-
ing, however, qRT-PCR arrays capable of detecting gen-
ome wide expression are not yet commercially available.
Moreover, additional breast tumor mRNA is unfortu-
nately not available for confirming our microarray and/
or NIS immunohistochemical staining results by quanti-
tative RT-PCR.
It is not known whether NIS is modulated at the post-
mRNA level in breast cancer. It has been reported that
34-96% of breast tumors express NIS mRNA [5,9,30].
However, Moon et al. [5] was the only study to quantify
NIS mRNA levels among breast tumors by competitive
RT-PCR followed by densitometry of ethidium bromide
staining. Interestingly, Moon et al. [5] reported that
nearly all breast tumors had NIS mRNA levels compar-
able to that of peri-tumoral normal breast tissues. More-
over, the overlap in mRNA levels among breast tumors
with and without detectable
99mTc pertechnetate uptake
[5] further suggests that NIS may be regulated at the
post-mRNA level. Accordingly, a correlation analysis in
which NIS mRNA levels detected by a more sensitive
qRT-PCR assay compared with corresponding cell sur-
face NIS protein levels among breast tissues should be
performed to elucidate the extent of post mRNA NIS
regulation. However, the variability in total NIS protein
(combination of intracellular and cell surface NIS pro-
tein) among breast tumors remains debatable. Indeed,
NIS cell surface trafficking impairments that result in
the accumulation of intracellular NIS immunostaining
has been suggested to occur in breast cancer [3,6]. How-
ever, our recent study [24] and Peyrottes et al. [37] indi-
cated that intracellular anti-NIS antibody
immunostaining may be non-specific. Finally, gene
expression profiles associated with cell surface NIS
levels may not only reflect differences in NIS expression,
but also differences in NIS protein stability and NIS cell
surface trafficking. Nevertheless, our breast cancer
microarray analysis did not identify cell signaling factors
previously reported to modulate NIS cell surface locali-
zation, such as the proto-oncogene PTTG-binding factor
(PBF) [38] or phosphatidylinositol-3 kinase (PI3K) [7].
The biological relationship between CARS and NIS
remains uncertain. Interestingly, while CARS is best
known for its role in the ligation of cysteine to tRNA
during protein translation, its expression has also been
associated with breast cancer [39]. CARS is located on
chromosome 11p15.5, one of the most highly imprinted
chromosomal regions. Many genes on chromosome
11p15.5, including insulin growth factor II (IGF II), are
susceptible to loss of imprinting (LOI), in which both
paternal and maternal alleles are aberrantly expressed
during breast cancer progression [40]. In fact, IGF II,
has not only been reported to have increased expression
in breast tumors compared to normal breast tissues, it
has also been reported to transiently increase NIS
expression in MCF-7 breast cancer cells [41]. Thus, the
positive association between CARS mRNA and cell sur-
face NIS protein in breast tumors could be contributed
indirectly by the location of CARS on chromosome
11p15.5. It would therefore be interesting to further
explore the relationship between CARS and NIS expres-
sion by determining whether siRNA-mediated loss of
CARS function interferes with functional NIS expression
in MCF-7 breast cancer cells.
Finally, the TMA selected to perform CARS immu-
nostaining contained breast tumors categorized as ER+
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Page 11 of 14or triple negative (ER-, PR- or Her-2/neu). Since triple-
negative breast tumors are not synonymous with basal
breast tumors [reviewed in [42]], it would be interesting
to further examine whether the association between
CARS and cell surface NIS protein level is restricted to
ER+ breast tumors.
Conclusions
NIS modulation among various breast tumors mainly
occurs at the translational and/or post-translational
levels. The cysteinyl-tRNA synthetase is highly asso-
ciated with cell surface NIS protein levels in breast
tumors of the ER-positive subtype. Further investigation
on biomarkers correlated with cell surface NIS protein
levels within each breast cancer molecular subtype may
lead to tailored strategies enabling NIS-targeted radio-
nuclide therapy for subsets of breast cancer patients.
Additional material
Additional file 1: Cluster analysis of 138 genes identified to be
significantly up- or down-regulated with tRA treatment compared
DMSO vehicle in MCF-7 cells, as determined by Linear Models
analysis. MCF-7 human breast cancer cells were treated with DMSO
vehicle or tRA (1 μM) for 12 hours, total RNA was harvested, genome-
wide expression was detected by oligonucleotide microarray (Affymetrix
HG U133 Plus 2.0) and genome-wide expression was compared between
treatments by Linear Model analysis. Significance was assigned to 138
genes with a false discovery rate ≤0.045% and a p-value less than
0.00045. The heat map shows expression of these 138 genes in tRA- and
DMSO vehicle-treated MCF-7 cells from two independent trials. Twenty
eight genes were significantly up-regulated and 110 genes were
significantly down-regulated in tRA-treated MCF-7 cells compared to
DMSO vehicle control, although the NIS gene was not identified among
them. Genes with high expression are denoted in red and genes with
low expression are denoted in green. No genes were commonly
identified by both the MCF-7 cell model and breast tumor analyses.
Additional file 2: Cluster analysis of 44 genes identified to be
significantly up- or down-regulated in cell surface NIS-positive
breast tumors compared to cell surface NIS-negative breast tumors
by Linear Models analysis. The Linear Models analysis compared gene
expression of 4 breast tumors considered to be negative for cell surface
NIS protein (0+) to 5 tumors considered to be strongly positive for cell
surface NIS protein (2+/3+). (A) Breast tumor IDs, molecular subtypes and
cell surface NIS protein levels of breast tumors are indicated on the heat
map. Significance was assigned to genes with a False Discovery Rate
threshold of ≤0.038% and a p-value < 0.0004. The Linear Models analysis
identified 42 genes to be significantly up-regulated and 2 genes to be
significantly down-regulated in cell surface NIS-positive tumors compared
to cell surface NIS-negative tumors. The cluster analysis shown in the
heat map above appeared to cluster ER+ and HER-2/neu breast tumors
according to molecular subtype and, within the ER+ molecular subtype,
breast tumors appeared to group according to the level of cell surface
NIS protein. In general, gene clusters capable of distinguishing between
NIS-positive and NIS-negative ER+ and Her-2/neu breast tumors could
not be identified. In contrast, cluster analysis distinguished between cell
surface NIS-positive and cell surface NIS-negative basal breast tumors.
High gene expression is denoted in red and low gene expression is
denoted in green on the heat map. (B) The box and whisker plot
examines and compares normalized mRNA expression of IGFBP2 and
SPIB among breast tumors scored as 0, 0/1+, 1+, 1+/2+, 2+ or 3+ for cell
surface NIS protein. The length of the box represents the interquartile
range (i.e., the middle 50% of the data). The median (line through the
middle of each box), the lower quartile (bottom line of each box), and the
upper quartile (top line of each box) are also specified on the plot for
each level of cell surface NIS protein. The sample minimum and
maximum values are represented as T-shaped lines extending from the
ends of the box. Maximum outliers (gray squares) and minimum outliers
(black diamonds) are also plotted.
Additional file 3: Genes identified to be positively- or negatively-
correlated with cell surface NIS protein levels in breast cancer. The
(A) Pearson and (B) Spearman rank correlation analyses compared gene
expression of 24 breast tumors to identify genes that highly correlate
with cell surface NIS protein levels. The heat maps are labeled with
breast tumor IDs, molecular subtypes, and cell surface NIS protein levels
corresponding to each breast tumor. Significance was assigned to genes
with a correlation coefficient greater than 0.6 in conjunction with a p-
value < 0.002. Sixty three genes were positively correlated (n = 44) or
inversely correlated (n = 19) with NIS expression by Pearson correlation
and 64 genes were positively (n = 42) or negatively (n = 22) correlated
with cell surface NIS protein levels by Spearman rank correlation. High
gene expression is shown in red and low gene expression is shown in
green. (C) The box and whisker plots examine and compare normalized
mRNA expression of two of the most highly correlated genes identified
by both analyses, QRICH1 and ND6, among breast tumors scored as 0, 0/
1+, 1+, 1+/2+, 2+ or 3+ for cell surface NIS protein. The length of the
box represents the interquartile range (i.e., the middle 50% of the data).
The median (line through the middle of each box), the lower quartile
(bottom line of each box), and the upper quartile (top line of each box)
are also specified on the plot for each level of cell surface NIS protein.
The sample minimum and maximum values are represented as T-shaped
lines extending from the ends of the box. Maximum outliers (gray
squares) and minimum outliers (black diamonds) are also plotted.
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